Gerald S Falchook

15PUBLICATIONS
138CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 15, 2026
SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review.

|Mar 04, 2026
Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer.

Susan Slovin, Xin Gao, Xiao X Wei

|Dec 31, 2025
AXL Inhibitors in Oncology Clinical Trials: A Review.

Ethan Quach, Farahnoz Sanginova, Anish Cheruku

|Nov 06, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

|Aug 29, 2025
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|Apr 11, 2025
B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review.

Meave Phipps, Gerald S Falchook

Pageof 3

Frequent Collaborators

3 joint publications

Meredith McKean

2 joint publications

Suzanne Jones

2 joint publications

Judy S Wang

2 joint publications

Elisa Fontana